Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa

BACKGROUND: Lamivudine (3TC) is a potent inhibitor of both Hepatitis B virus (HBV) and Human Immunodeficiency Virus (HIV) replication and is part of first-line highly active antiretroviral therapy (HAART) in the Gambia. Unfortunately, the effectiveness of 3TC against HBV is limited by the emergence...

Descripción completa

Detalles Bibliográficos
Autores principales: Stewart, Balint, Jobarteh, Modou L, Sarge-Njie, Ramu, Alabi, Abraham, de Silva, Thushan, Peterson, Kevin, Peterson, Ingrid, Whittle, Hilton, Rowland-Jones, Sarah, Jaye, Assan, Cotten, Matthew, Mendy, Maimuna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292846/
https://www.ncbi.nlm.nih.gov/pubmed/22195774
http://dx.doi.org/10.1186/1756-0500-4-561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292846/
https://www.ncbi.nlm.nih.gov/pubmed/22195774
http://dx.doi.org/10.1186/1756-0500-4-561

Ejemplares similares